OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐ CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma

HTML

Year: 2013
Type: article
Study design: Clinical Trial
Source: British Journal of Haematology
DOI: 10.1111/bjh.12565
Authors: Jonathan L. Kaufman, Ruben Niesvizky, Edward A. Stadtmauer, Asher Chanan‐Khan, David Siegel, Heather Horne, William A. Wegener, David M. Goldenberg
Institutions: Emory University, Winship Cancer Institute, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Abramson Cancer Center, University of Pennsylvania, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Immunomedics (United States)
Language: English

Topic: Multiple Myeloma Research and Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: CD74, multiple myeloma, relapsed/refractory multiple myeloma, monoclonal antibody therapy, dose escalation, pharmacokinetics, pharmacodynamics, B-cell depletion, drug conjugates, anti-drug antibody, stable disease
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2017357058
FWCI: 5.643
Cites: 35
Cited by: 131
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security